Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Benjamin Hohl currently holds 51,000 shares of Enliven Therapeutics, Inc. (ELVN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Benjamin Hohl has been a net seller of ELVN stock. They have purchased $0 and sold $1.8M worth of shares.
Benjamin Hohl's most recent insider trade was on Mar 6, 2026, when they sold 10,000 shares at $29.58 per share.
Benjamin Hohl serves as Executive at Enliven Therapeutics, Inc. (ELVN). They have executed 77 insider transactions totaling $1.8M over their tenure at the company.
Benjamin Hohl holds the position of Executive at Enliven Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 2 years and currently hold a stake valued at $0.
Benjamin Hohl has shown a selling trading pattern, with $0 in total purchases and $1.8M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Benjamin Hohl was on Mar 6, 2026, when they sold $295.8K worth of ELVN shares. This transaction involved 10,000 shares at $29.58 per share.
Benjamin Hohl currently owns 51,000 shares of Enliven Therapeutics, Inc. (ELVN), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Benjamin Hohl's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Benjamin Hohl has 77 Form 4 filings on record as an insider at Enliven Therapeutics, Inc..
Set alerts for Benjamin Hohl and 40,000+ other insiders.